Moderna to Pay Up to $2.25 Billion to Settle Long-Running COVID Vaccine Patent Dispute

news.law March 5, 2026

Moderna has agreed to pay Genevant Sciences, a ‌subsidiary of Roivant Sciences, and Arbutus ‌Biopharma up to $2.25 billion to settle a long-running legal fight over the technology that made its COVID-19 vaccine possible, the companies said on Tuesday.

Under the deal, ‌Moderna will ⁠pay $950 million upfront in July 2026, with an additional $1.3 billion ⁠that depends on the outcome of a separate legal appeal.

City of Lexington, Kentucky Settles Lawsuit for $1.2M After Woman's Wrongful Arrest

Minnesota Sues Trump Admin In Attempt to Stop It From Holding Back Medicaid Funds